27 May 2015

Cyclo-Progynova (Estradiol valerate / Norgestrel) - United Kingdom

ATC: G03FB
GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
PROGESTOGENS AND ESTROGENS, SEQUENTIAL PREPARATIONS
Cyclo-Progynova

Last Updated on 27 May 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Cyclo-Progynova Indication

Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in perimenopausal and postmenopausal women.

Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

 

Cyclo-Progynova Generic Name

Estradiol valerate / Norgestrel

Type

POM

Summary Product Characteristics (SPCs) Links
SPC - Cyclo-Progynova 2mg (external site)

Related Learning Zones

Hyperammonaemia Knowledge Centre

Hyperammonaemia Knowledge Centre

The Hyperammonaemia Knowledge Centre has been developed to raise awareness of this rare yet potentially deadly condition. Using this resource, healthcare professionals are encouraged to recognise the signs and symptoms of hyperammonaemia and begin the correct treatment immediately.

Prostate Cancer Learning Hub

Prostate Cancer Learning Hub

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer. The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer.

Cyclo-Progynova Marketing Information

Cyclo-Progynova Generic Name
Estradiol valerate / Norgestrel
Marketing Company
Meda Pharmaceuticals Ltd
Drug Type
POM
Date of Issue, Marketing Authority 01/12/2009

Related Drugs - Women's Health and Obs/Gyn

Back to top